Gene interactions and pathways from curated databases and text-mining
Future Oncol 2012, PMID: 23231513

Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Józwiak, Sergiusz; Stein, Karen; Kotulska, Katarzyna

Everolimus (RAD001), a mTOR inhibitor, was initially used as an immunosuppressant in organ transplant patients; however, it also has significant antineoplastic properties. In patients with subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis complex who are not candidates for surgery, single-agent everolimus has demonstrated the ability to significantly reduce SEGA volume with good tolerability. In the Phase III, randomized, placebo-controlled trial, everolimus was associated with a SEGA response rate of 35% compared with 0% in the placebo group. The most common adverse events in clinical trials were stomatitis/mouth ulceration and upper respiratory tract infections, and most adverse events were grade 1 or 2; grade 4 events were rare.

Diseases/Pathways annotated by Medline MESH: Astrocytoma, Oral Ulcer, Stomatitis, Tuberous Sclerosis
Document information provided by NCBI PubMed

Text Mining Data

mTOR ⊣ RAD001: " Everolimus ( RAD001 ), a mTOR inhibitor , was initially used as an immunosuppressant in organ transplant patients ; however, it also has significant antineoplastic properties "

Manually curated Databases

No curated data.